倍他乐克联合胺碘酮、门冬氨酸钾镁对急性心肌梗塞早期并发室颤的救治  

Effect of betaloc and amiodalone intravenous injection in patients with acute myocardium infarction early complicated ventricular fibrillation

作　　者：殷实[1] 黄亚辉[1] 公兰兰 

机构地区：[1]佳木斯中心医院心内科,黑龙江佳木斯154002

出　　处：《心血管康复医学杂志》2007年第2期168-169,共2页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:评价静脉应用倍他乐克联合胺碘酮、门冬氨酸钾镁治疗急性心肌梗塞(AMI)早期并发恶性心律失常(室颤)临床疗效。方法:选择2004年1月～2005年1月住院的6例AMI患者,在常规治疗的基础上,反复电除颤室颤不能得以控制,随即应用倍他乐克5ml分3次静注,同时静点胺碘酮450mg+5%葡萄糖注射液(15滴/min),门冬氨酸钾镁4.0+5%葡萄糖注射液。结果:6例中抢救成功5例,死亡1例,存活率:83.33%。除在应用倍他乐克开始阶段2例表现为一过性低血压,1例因心功不全猝死,未见心功能恶化及致心律失常作用。结论:急性心肌梗塞早期静脉应用倍他乐克联合胺碘酮,门冬氨酸钾镁能够有效控制室颤,降低死亡率。Objective： To study the effect of betaloc and amiodalone intravenous injection in patients with acute myocardium infarction （AMI） early complicated ventricular fibrillation （VF）. Methods： The 6 AMI patients complicated VF were no controled VF by routine therapy and repeated electrical defibrillation. Then they were treated with betaloc, amiodalone and potassium magnesium aspartate intravenous injection. Results： The 5 AMI patients complicated VF （83.33%） were survival after treat. Except one patient died because heart failure there was no severity adverse reaction. Conclusion： The betaloc, amiodalone and potassium magnesium aspartate intravenous injection may control ventricular fibrillation and decrease mortality in early AMI patients complicated ventricular fibrillation.

关 键 词：倍达乐克 胺碘酮 心肌梗塞 心律失常 

分 类 号：R542.22[医药卫生—心血管疾病]